Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-Analysis.

Medicine (Baltimore) · 2015 · PMC4616831 · PMID 26426637

Europe PMC DOI

hedged sentence

0.8360

closest p · 16.7× alpha

0.8360

boldest claim

The sentences

a weak trendP = 0.836not close (p > 0.1)

Subjects carrying the CC genotype maintained a weak trend toward a better response rate to neoadjuvant therapy compared with subjects with the CT-TT genotype (OR = 1.11, 95% CI = 0.83–1.48, heterogeneity P = 0.836) (Fig. 2 ).

also in 1,404 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.